In October 2021, the drug manufacturer submitted a marketing authorisation application to the EMA and a priority review voucher to the US FDA for the regulatory approval of tirzepatide in type 2 diabetes, leading to an expected review time of 8 months from the date of submission [12]
Self-pay for GLP-1s Many insurance plans will no longer cover GLP-1 medications for weight loss
DOI: 10.1002/(SICI)1099-1387(200001)6:13.0.CO;2-V Research Use Only: All products are intended exclusively for in-vitro laboratory research
Demand for prescriptions has been so high that suppliers often struggle to meet demand
It will allow a lot of people who are locked into high-risk obesity to finally lose weight, to reset and then start doing the kind of things that will address the root causes of obesity. Most Favored Nation pricing In his second term, Trump has revived a controversial initiative to base drug prices in the US on those in other developed countries, so-called Most Favored Nation pricing
*Correspondence: Linda de Bont, [email protected] Rouhier, [email protected] This article was submitted to Plant Abiotic Stress, a section of the journal Frontiers in Plant Science Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
